Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Invivyd (IVVD) and Damo...

Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY). Enlive...

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)

Enliven Therapeutics ( ($ELVN) ) just unveiled an announcement. Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2026,...

Enliven Therapeutics Expands Authorized Shares After Stockholder Vote

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Enliven Therapeutics, with a price target of $62.00. Accor...

Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Partners (MOLN), Enliven Therapeutics (ELV...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$40.36	+9.08%	5.10M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$40.36	+9.1%	5.10M
3
4
5
6

ELVN

ELVN

Recent News for ELVN

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel